A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer

PURPOSE: The Phase III POTENT trial demonstrated the efficacy of adding S-1 to adjuvant endocrine therapy for estrogen receptor-positive, HER2-negative early breast cancer. We investigated the efficacy of S-1 across different recurrence risk subgroups. METHODS: This was a post-hoc exploratory analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Masahiro, Imoto, Shigeru, Ishida, Takanori, Ito, Yoshinori, Iwata, Hiroji, Masuda, Norikazu, Mukai, Hirofumi, Saji, Shigehira, Ikeda, Takafumi, Haga, Hironori, Saeki, Toshiaki, Aogi, Kenjiro, Sugie, Tomoharu, Ueno, Takayuki, Ohno, Shinji, Ishiguro, Hiroshi, Kanbayashi, Chizuko, Miyamoto, Takeshi, Hagiwara, Yasuhiro, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564670/
https://www.ncbi.nlm.nih.gov/pubmed/37676450
http://dx.doi.org/10.1007/s10549-023-07099-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564670/
https://www.ncbi.nlm.nih.gov/pubmed/37676450
http://dx.doi.org/10.1007/s10549-023-07099-4

Ejemplares similares